论文部分内容阅读
目的:探讨孟鲁司特钠治疗成人咳嗽变异性哮喘(CAV)的临床效果。方法:将2008年1月-2013年12月我院收治的65例CAV患者随机分为观察组(n=33)和对照组(n=32),两组患者均给予糖皮质激素、β_2受体激动剂及氨茶碱等对症治疗;观察组在此基础上予以孟鲁司特钠10 mg,每晚睡前口服,比较两组治疗的总有效率、肺功能改善情况及不良反应发生情况。结果:观察组的总有效率显著高于对照组(90.9%vs 65.6%,P<0.05);两组患者治疗后PEF和FEV1均明显优于治疗前(P<0.05),且观察组治疗后的PEF和FEV1均明显优于对照组治疗后(P<0.05);两组患者均未出现明显不良反应。结论:CAV治疗中常规应用孟鲁司特钠可提高临床效果。
Objective: To investigate the clinical efficacy of montelukast sodium in the treatment of adult cough variant asthma (CAV). Methods: Sixty-five patients with CAV admitted to our hospital from January 2008 to December 2013 were randomly divided into observation group (n = 33) and control group (n = 32). Both groups were given glucocorticoid, Body agonists and aminophylline and other symptomatic treatment; the observation group on the basis of montelukast sodium 10 mg orally every night before going to bed, compared the total effective rate of treatment of two groups, lung function improvement and adverse reactions . Results: The total effective rate in observation group was significantly higher than that in control group (90.9% vs 65.6%, P <0.05). PEF and FEV1 in both groups were significantly better than those before treatment (P <0.05) PEF and FEV1 were significantly better than the control group after treatment (P <0.05); no significant adverse reactions in both groups. Conclusion: The routine application of montelukast sodium in CAV therapy can improve the clinical effect.